NCT06916065COMPLETEDanonymous

A Phase 1, Open-Label, Single and Multiple Dose Study to Investigate the Safety, Tolerability, and Relative Bioavailability of Single and Multiple Weekly Subcutaneous Doses of Eloralintide, and Single and Multiple Weekly Subcutaneous Doses of Eloralintide With Tirzepatide in Participants With Overweight or Obesity

Sponsor

Source record

Eli Lilly and Company

Phase

Source record

Phase 1

Modality

AI-normalized

small molecule

Target

AI-normalized

Eloralintide (LY3841136) is a peptide designed to target the GLP-1 receptor pathway, potentially enhancing metabolic regulation and weight management. Tirzepatide, a dual GIP and GLP-1 receptor agonist, may synergistically enhance the effects of eloralintide.

Indication / condition

AI-normalized

Overweight

Intervention

Source record

Eloralintide and Tirzepatide, Eloralintide

Related intelligence directories

Indication directory: Overweight Modality directory: small molecule Target directory: Eloralintide (LY3841136) is a peptide designed to target the GLP-1 receptor pathway

Source & freshness

Source record

NCT ID

NCT06916065

Original source

ClinicalTrials.gov

Source last updated

Detailed source ingestion pending.

Ingested at

Jun 25, 2026

Internal sync

Jun 25, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT06916065

Title

A Phase 1, Open-Label, Single and Multiple Dose Study to Investigate the Safety, Tolerability, and Relative Bioavailability of Single and Multiple Weekly Subcutaneous Doses of Eloralintide, and Single and Multiple Weekly Subcutaneous Doses of Eloralintide With Tirzepatide in Participants With Overweight or Obesity

Sponsor

Eli Lilly and Company

Status

COMPLETED

Phase

Phase 1

Condition raw

Overweight, Obesity

Condition normalized

Overweight, Obesity

Modality raw

small molecule

Modality normalized

small molecule

Target raw

Target normalized

Interventions

Eloralintide and Tirzepatide, Eloralintide

Public preview

Source record

Eli Lilly's Phase 1 trial of eloralintide, both alone and in combination with tirzepatide, addresses the growing obesity epidemic, a significant market opportunity projected to exceed $30 billion by 2025. The trial's focus on safety, tolerability, and pharmacokinetics positions Lilly to compete in the obesity treatment landscape, particularly against established GLP-1 receptor agonists and emerging therapies. Successful outcomes could lead to further development and potential market entry, enhancing Lilly's portfolio in metabolic disorders and weight management.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Early access offer

Subscribe with code FOUNDERS5 for a 5-day premium trial.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Phase 1, Open-Label, Single and Multiple Dose Study to Investigate the Safety, Tolerability, and Relative Bioavailability of Single and Multiple Weekly Subcutaneous Doses of Eloralintide, and Single and Multiple Weekly Subcutaneous Doses of Eloralintide With Tirzepatide in Participants With Overweight or Obesity

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 25, 2026

Report code

NCT06916065-Jun 25, 2026

NCT ID

NCT06916065

Status

COMPLETED

Phase

Phase 1

Sponsor

Eli Lilly and Company

Executive brief

Investment-Ready Snapshot

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedDetailed source ingestion pending.

Internal syncJun 25, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT06916065

Indication

Overweight

Modality

small molecule

Target

Intervention

Eloralintide and Tirzepatide, Eloralintide

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.